礼来高管表示,Orforglipron的申报文件将在本季度提交监管机构,同时指出审批路径的选择将由政府决定。
礼来高管表示,Orforglipron的申报文件将在本季度提交监管机构,同时指出审批路径的选择将由政府决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.